Develops drugs for anxiety and stressor-related disorders.
Jun 2026Revenue $1.17M/yrExpenses $17.6M/yr
No trendCash runway ≈ 1.6 years from Jun 2026
Figures by year
When will Neuphoria Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.17M and expenses $17.6M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Jun 2026 | $1.17M | $17.6M | −$16.5M |
| Jun 2025 | $15.6M | $16.8M | −$1.13M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.